# BioPharmSignal LiveFeed

A current stream of biotech company news, clinical updates, FDA events, financing headlines, partnerships, and commercial launch updates.

Canonical URL: https://biopharmsignal.com/livefeed

## Latest News

- 2026-08-07 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e139524a) — Source: Oric Pharmaceuticals, Inc.
- 2026-08-07 20:20 EST — SRRK — [Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date](https://biopharmsignal.com/news/SRRK/scholar-rock-announces-fda-review-of-apitegromab-biologics-license-application-b-ba9f6662) — Source: Scholar Rock
- 2026-08-07 20:05 EST — AMWL — [Amwell makes grant to new employees under inducement plan](https://biopharmsignal.com/news/AMWL/amwell-makes-grant-to-new-employees-under-inducement-plan-8fec64da) — Source: American Well
- 2026-08-07 20:05 EST — ENTX — [Entera Announces Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/ENTX/entera-announces-second-quarter-2026-financial-results-and-business-updates-986e7094) — Source: Entera Bio
- 2026-08-07 20:05 EST — SYRE — [Spyre Therapeutics Announces Grants of Inducement Awards](https://biopharmsignal.com/news/SYRE/spyre-therapeutics-announces-grants-of-inducement-awards-733c2ae4) — Source: Spyre Therapeutics, Inc.
- 2026-08-07 20:05 EST — OCUL — [Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-648c6f73) — Source: Ocular Therapeutix
- 2026-08-07 20:01 EST — KNSA — [Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/KNSA/kiniksa-pharmaceuticals-to-present-at-canaccord-genuity-46th-annual-growth-confe-e6022b66) — Source: Kiniksa
- 2026-08-07 20:01 EST — ATYR — [aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-second-quarter-2026-results-program-prioritization-and-cor-fd0d7566) — Source: aTyr Pharma
- 2026-08-07 20:01 EST — NTLA — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-220d5920) — Source: Intellia
- 2026-08-07 20:00 EST — ARQT — [Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-662493df) — Source: Arcutis Biotherapeutics
- 2026-08-07 14:51 EST — PGNY — [Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference](https://biopharmsignal.com/news/PGNY/progyny-inc-to-present-at-the-canaccord-genuity-annual-growth-conference-b39cf730) — Source: Progyny
- 2026-08-07 13:25 EST — FEMY — [Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million](https://biopharmsignal.com/news/FEMY/femasys-secures-30-million-private-placement-with-potential-proceeds-of-up-to-90-9edc7de9) — Source: FEMASYS
- 2026-08-07 12:45 EST — RCEL — [AVITA Medical Announces Participation at Canaccord Genuity Growth Conference](https://biopharmsignal.com/news/RCEL/avita-medical-announces-participation-at-canaccord-genuity-growth-conference-d565c588) — Source: Avita Medical
- 2026-08-07 12:35 EST — XBIO — [Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-reports-second-quarter-2026-financial-results-and-highlights-1142fce8) — Source: Xenetic
- 2026-08-07 12:30 EST — QNRX — [Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-to-announce-corporate-update-and-second-quarter-2026-finan-b30abd1a) — Source: Quoin
- 2026-08-07 12:30 EST — NBIX — [Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-590bdb3d) — Source: Neurocrine Biosciences
- 2026-08-07 12:00 EST — PCRX — [Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PCRX/pacira-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-dcb742e9) — Source: Pacira BioSciences
- 2026-08-07 12:00 EST — TSHA — [Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635--1abe04ba) — Source: Taysha Gene Therapies
- 2026-08-07 12:00 EST — HUMA — [Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026](https://biopharmsignal.com/news/HUMA/humacyte-to-announce-2026-second-quarter-financial-results-and-provide-business--20c7f207) — Source: Humacyte
- 2026-08-07 12:00 EST — BIAF — [bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-second-quarter-2026-results-and-continued-stron-0f0ca732) — Source: bioAffinity Technologies, Inc.
- 2026-08-07 11:30 EST — KURA — [Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KURA/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-31057b4b) — Source: Kura Oncology
- 2026-08-07 11:30 EST — SNGX — [Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SNGX/soligenix-announces-recent-updates-and-second-quarter-2026-financial-results-6b343331) — Source: SOLIGENIX
- 2026-08-07 11:05 EST — TMCI — [Treace Medical Concepts Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/TMCI/treace-medical-concepts-reports-second-quarter-2026-financial-results-7a569b1c) — Source: Treace Medical Concepts
- 2026-08-07 11:00 EST — RPID — [Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-reports-second-quarter-2026-financial-results-96221a52) — Source: Rapid Micro Biosystems
- 2026-08-07 11:00 EST — NERV — [Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-busines-c01af06c) — Source: Minerva Neuroscience
- 2026-08-07 11:00 EST — GYRE — [Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update](https://biopharmsignal.com/news/GYRE/gyre-therapeutics-reports-second-quarter-2026-and-year-to-date-financial-results-4aa1bb4b) — Source: Gyre Therapeutics
- 2026-08-07 11:00 EST — CBIO — [Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-second-quarter-2026-and-year-to-date-financial-results-1f32e996) — Source: Catalyst Biosciences
- 2026-08-07 11:00 EST — KPRX — [Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/KPRX/kiora-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-7b61887b) — Source: Kiora Pharmaceuticals
- 2026-08-07 11:00 EST — RNAC — [Cartesian Therapeutics Announces New Employment Inducement Grants](https://biopharmsignal.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-245c2e4a) — Source: Cartesian Therapeutics
- 2026-08-07 11:00 EST — PPBT — [Purple Biotech Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/PPBT/purple-biotech-reports-second-quarter-2026-financial-results-bf7cc915) — Source: Purple Biotech
- 2026-08-07 10:50 EST — ANIP — [ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ANIP/ani-pharmaceuticals-reports-record-second-quarter-2026-financial-results-68f15c4b) — Source: ANI Pharmaceuticals
- 2026-08-07 10:30 EST — EMBC — [Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results](https://biopharmsignal.com/news/EMBC/embecta-corp-reports-third-quarter-fiscal-2026-financial-results-99a5ad0e) — Source: Embecta
- 2026-08-07 10:00 EST — EMBC — [embecta Announces Quarterly Cash Dividend](https://biopharmsignal.com/news/EMBC/embecta-announces-quarterly-cash-dividend-971e0322) — Source: Embecta
- 2026-08-06 22:24 EST — TNGX — [Tango Therapeutics Announces Executive Chair Transition](https://biopharmsignal.com/news/TNGX/tango-therapeutics-announces-executive-chair-transition-f7c96c55) — Source: Tango Therapeutics
- 2026-08-06 22:15 EST — BIIB — [Biogen Completes Acquisition of RayThera Inc.](https://biopharmsignal.com/news/BIIB/biogen-completes-acquisition-of-raythera-inc-bef275f3) — Source: Biogen
- 2026-08-06 21:38 EST — BSEM — [BioStem Technologies Announces Nasdaq Uplisting](https://biopharmsignal.com/news/BSEM/biostem-technologies-announces-nasdaq-uplisting-1112648d) — Source: BioStem Technologies
- 2026-08-06 21:15 EST — LMAT — [LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference](https://biopharmsignal.com/news/LMAT/lemaitre-to-participate-in-the-11th-annual-needham-virtual-medtech-diagnostics-1-1522d9d5) — Source: LeMaitre Vascular
- 2026-08-06 20:35 EST — ACRS — [Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)](https://biopharmsignal.com/news/ACRS/aclaris-therapeutics-receives-fast-track-designation-for-modzatinib-ati-2138-for-9a314e80) — Source: Aclaris Therapeutics
- 2026-08-06 20:30 EST — MGTX — [MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-3ee9d0a1) — Source: MeiraGTx
- 2026-08-06 20:30 EST — CLLS — [Cellectis Reports Financial Results for the Second Quarter 2026](https://biopharmsignal.com/news/CLLS/cellectis-reports-financial-results-for-the-second-quarter-2026-b233bf32) — Source: Cellectis
- 2026-08-06 20:16 EST — VTAK — [Flyte Achieves Record Revenues in July](https://biopharmsignal.com/news/VTAK/flyte-achieves-record-revenues-in-july-65ffa3f3) — Source: Catheter Precision
- 2026-08-06 20:15 EST — CGTX — [Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update](https://biopharmsignal.com/news/CGTX/cognition-therapeutics-reports-financial-results-for-the-second-quarter-2026-and-dd1f3bfc) — Source: Cognition Therapeutics
- 2026-08-06 20:15 EST — CTMX — [CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-q2-2026-financial-results-and-provides-business-up-f66d0912) — Source: CytomX Therapeutics, Inc.
- 2026-08-06 20:15 EST — GMED — [Globus Medical Reports Second Quarter 2026 Results](https://biopharmsignal.com/news/GMED/globus-medical-reports-second-quarter-2026-results-558d9243) — Source: Globus Medical
- 2026-08-06 20:15 EST — YOU — [CLEAR Launches Corporate Memberships, Bringing Seamless Travel Benefits to Business Travelers From Home to Gate](https://biopharmsignal.com/news/YOU/clear-launches-corporate-memberships-bringing-seamless-travel-benefits-to-busine-2d9b963b) — Source: Clear Secure Inc
- 2026-08-06 20:15 EST — XFOR — [X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XFOR/x4-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-co-879da21b) — Source: X4 Pharmaceuticals
- 2026-08-06 20:10 EST — NEPH — [Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026](https://biopharmsignal.com/news/NEPH/nephros-announces-strong-financial-results-for-quarter-ended-june-30-2026-e71fa082) — Source: Nephros
- 2026-08-06 20:08 EST — SLDB — [Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/SLDB/solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-bus-f3dbe474) — Source: Solid Biosciences
- 2026-08-06 20:06 EST — IRTC — [iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care](https://biopharmsignal.com/news/IRTC/irhythm-to-acquire-vitalconnect-expanding-its-cardiac-monitoring-platform-across-364d9af8) — Source: iRhythm
- 2026-08-06 20:05 EST — LYEL — [Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-sec-9330d763) — Source: Lyell Immunopharma
- 2026-08-06 20:05 EST — GPCR — [Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-second-quarter-2026-financial-results-and-recent--f516f2ee) — Source: Structure Therapeutics
- 2026-08-06 20:05 EST — ORGO — [Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ORGO/organogenesis-holdings-inc-reports-second-quarter-2026-financial-results-9a026aba) — Source: Organogenesis
- 2026-08-06 20:05 EST — CVRX — [CVRx Reports Second Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/CVRX/cvrx-reports-second-quarter-2026-financial-and-operating-results-01c03331) — Source: CVRx
- 2026-08-06 20:05 EST — OCS — [Oculis Reports Q2 2026 Financial Results and Provides Company Update](https://biopharmsignal.com/news/OCS/oculis-reports-q2-2026-financial-results-and-provides-company-update-e5367096) — Source: Oculis
- 2026-08-06 20:05 EST — VRCA — [Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-reports-second-quarter-2026-financial-results-10f4a960) — Source: Verrica Pharmaceuticals
- 2026-08-06 20:05 EST — INGN — [Inogen Announces Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/INGN/inogen-announces-second-quarter-2026-financial-results-83867f19) — Source: Inogen
- 2026-08-06 20:05 EST — ZNTL — [Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-reports-second-quarter-2026-financial-results-and-busin-c4940e1e) — Source: Zentalis
- 2026-08-06 20:05 EST — ECOR — [electroCore Announces Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ECOR/electrocore-announces-second-quarter-2026-financial-results-08dfc7f0) — Source: electroCore
- 2026-08-06 20:05 EST — ICCC — [ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026](https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-june-30-2-53516e1a) — Source: ImmuCell
- 2026-08-06 20:05 EST — VXRT — [Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/VXRT/vaxart-provides-business-update-and-reports-second-quarter-2026-financial-result-f6dfcbb4) — Source: Vaxart
- 2026-08-06 20:05 EST — APYX — [Apyx Medical Corporation Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/APYX/apyx-medical-corporation-reports-second-quarter-2026-financial-results-41096692) — Source: Apyx Medical
- 2026-08-06 20:05 EST — AORT — [Artivion Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/AORT/artivion-reports-second-quarter-2026-financial-results-66273319) — Source: Artivion
- 2026-08-06 20:05 EST — ALEC — [Alector Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ALEC/alector-reports-second-quarter-2026-financial-results-and-provides-business-upda-d57d0201) — Source: Alector
- 2026-08-06 20:05 EST — ARDX — [Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ARDX/ardelyx-reports-second-quarter-2026-financial-results-and-provides-business-upda-6ff72f66) — Source: Ardelyx
- 2026-08-06 20:05 EST — IRTC — [iRhythm Holdings Announces Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/IRTC/irhythm-holdings-announces-second-quarter-2026-financial-results-e4b2e270) — Source: iRhythm
- 2026-08-06 20:05 EST — RLAY — [Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates](https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-second-quarter-2026-financial-results-and-corporate-u-f325a004) — Source: Relay Therapeutics
- 2026-08-06 20:05 EST — ICUI — [ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance](https://biopharmsignal.com/news/ICUI/icu-medical-announces-second-quarter-2026-results-and-updates-its-fiscal-year-20-82f8d7f2) — Source: ICU Medical
- 2026-08-06 20:05 EST — MDGL — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-52cfb9fa) — Source: Madrigal
- 2026-08-06 20:05 EST — PLSE — [Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/PLSE/pulse-biosciences-reports-business-updates-and-second-quarter-2026-financial-res-4e89618c) — Source: Pulse Biosciences
- 2026-08-06 20:05 EST — HYPR — [Hyperfine, Inc. Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/HYPR/hyperfine-inc-reports-second-quarter-2026-financial-results-9a8e863d) — Source: Hyperfine
- 2026-08-06 20:03 EST — HCAT — [Health Catalyst Reports Second Quarter 2026 Results](https://biopharmsignal.com/news/HCAT/health-catalyst-reports-second-quarter-2026-results-bff66ad3) — Source: Health Catalyst
- 2026-08-06 20:02 EST — RCEL — [AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven](https://biopharmsignal.com/news/RCEL/avita-medical-reports-second-quarter-results-raises-2026-revenue-guidance-and-ex-2f35a8f6) — Source: Avita Medical
- 2026-08-06 20:01 EST — INAB — [IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/INAB/in8bio-reports-second-quarter-2026-financial-results-and-recent-business-highlig-81c5698f) — Source: IN8bio
- 2026-08-06 20:01 EST — VRCA — [Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-closes-credit-facility-for-up-to-27-5-million-in-non-dil-81cf3a45) — Source: Verrica Pharmaceuticals
- 2026-08-06 20:01 EST — PGNY — [Progyny, Inc. Announces Second Quarter 2026 Results](https://biopharmsignal.com/news/PGNY/progyny-inc-announces-second-quarter-2026-results-ca463ac9) — Source: Progyny
- 2026-08-06 20:01 EST — XENE — [Xenon Reports Q2 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/XENE/xenon-reports-q2-2026-financial-results-and-provides-business-update-5005aa04) — Source: Xenon
- 2026-08-06 20:01 EST — NAMS — [NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-39377bb8) — Source: NewAmsterdam Pharma
- 2026-08-06 20:01 EST — LCTX — [Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-second-quarter-2026-financial-results-and-prov-164fe544) — Source: Lineage Cell Therapeutics
- 2026-08-06 20:01 EST — ASND — [Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026](https://biopharmsignal.com/news/ASND/ascendis-to-report-second-quarter-2026-financial-results-and-provide-business-up-f021ee6b) — Source: Ascendis Pharma
- 2026-08-06 20:01 EST — DNLI — [Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-second-quarter-2026-financial-results-and-business-h-04a0e77e) — Source: Denali Therapeutics
- 2026-08-06 20:01 EST — CLDX — [Celldex Reports Second Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CLDX/celldex-reports-second-quarter-financial-results-and-provides-corporate-update-6d3ad2e0) — Source: Celldex Therapeutics
- 2026-08-06 20:01 EST — CRVS — [Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-provides-business-update-and-reports-second-quarter-2026--e0de761b) — Source: Corvus Pharmaceuticals
- 2026-08-06 20:01 EST — OM — [Outset Medical Reports Second Quarter 2026 Results](https://biopharmsignal.com/news/OM/outset-medical-reports-second-quarter-2026-results-9a4d1cac) — Source: Outset Medical
- 2026-08-06 20:01 EST — SENS — [Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SENS/senseonics-holdings-inc-reports-second-quarter-2026-financial-results-1a8e70d3) — Source: Senseonics
- 2026-08-06 20:01 EST — VYGR — [Voyager Reports Second Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/VYGR/voyager-reports-second-quarter-2026-financial-and-operating-results-b3aecbfa) — Source: Voyager Therapeutics
- 2026-08-06 20:01 EST — XRAY — [Dentsply Sirona Reports Second Quarter 2026 Results](https://biopharmsignal.com/news/XRAY/dentsply-sirona-reports-second-quarter-2026-results-61d81bd6) — Source: DENTSPLY SIRONA Inc.
- 2026-08-06 20:01 EST — NXTC — [NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/NXTC/nextcure-provides-business-update-and-reports-second-quarter-2026-financial-resu-b8c0c9e3) — Source: NextCure
- 2026-08-06 20:00 EST — REPL — [Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen](https://biopharmsignal.com/news/REPL/replimune-announces-fda-accelerated-approval-of-tudriqevtm-in-combination-with-n-9ad39372) — Source: Replimune Group
- 2026-08-06 20:00 EST — INMB — [INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress](https://biopharmsignal.com/news/INMB/inmune-bio-inc-announces-second-quarter-2026-results-and-highlights-regulatory-m-fcee152b) — Source: INmune Bio
- 2026-08-06 20:00 EST — CYTK — [Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CYTK/cytokinetics-reports-second-quarter-2026-financial-results-and-provides-business-f82f53a5) — Source: Cytokinetics
- 2026-08-06 16:00 EST — INKT — [MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium](https://biopharmsignal.com/news/INKT/mink-therapeutics-presents-early-observations-from-ongoing-phase-2-trial-at-the--34378519) — Source: MiNK Therapeutics, Inc.
- 2026-08-06 15:29 EST — NRSN — [NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada](https://biopharmsignal.com/news/NRSN/neurosense-completes-primec-pre-nds-process-and-advances-toward-december-2026-fi-0cca2aac) — Source: NeuroSense Therapeutics
- 2026-08-06 13:00 EST — SNOA — [Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA](https://biopharmsignal.com/news/SNOA/sonoma-pharmaceuticals-delivers-141-u-s-revenue-growth-in-fy-q1-60-total-revenue-637c5159) — Source: Sonoma Pharmaceuticals
- 2026-08-06 12:45 EST — OTLK — [Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-to-report-third-quarter-fiscal-year-2026-financial-results--3c6af746) — Source: Outlook
- 2026-08-06 12:35 EST — ICU — [SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026](https://biopharmsignal.com/news/ICU/seastar-medical-to-report-second-quarter-financial-results-on-august-12-2026-23d1e391) — Source: SeaStar Medical
- 2026-08-06 12:34 EST — CELC — [Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call](https://biopharmsignal.com/news/CELC/celcuity-schedules-release-of-second-quarter-2026-financial-results-and-webcast--d136ece1) — Source: Celcuity
- 2026-08-06 12:30 EST — RNXT — [RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors](https://biopharmsignal.com/news/RNXT/renovorx-announces-first-commercial-clinical-use-of-renovocath-in-sarcoma-patien-e5885230) — Source: RenovoRx
- 2026-08-06 12:30 EST — AQB — [AquaBounty Technologies Announces Expansion of Strategic Alternatives Review to Include Power Infrastructure Development Opportunities](https://biopharmsignal.com/news/AQB/aquabounty-technologies-announces-expansion-of-strategic-alternatives-review-to--127fa408) — Source: AquaBounty Technologies
- 2026-08-06 12:30 EST — VTGN — [Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder](https://biopharmsignal.com/news/VTGN/vistagen-announces-topline-results-for-repeat-dose-study-of-fasedienol-for-acute-d6fe0efe) — Source: Vistagen Therapeutics, Inc.
- 2026-08-06 12:19 EST — INKT — [MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates](https://biopharmsignal.com/news/INKT/mink-therapeutics-to-report-second-quarter-2026-financial-results-provide-clinic-55e96291) — Source: MiNK Therapeutics, Inc.